Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 60 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neovascular Age-Related Macular Degeneration (nAMD) Clear all
Active, not recruiting Phase 2Phase 3 Interventional

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD

NCT04704921
View directory record Official record
Conditions
AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, Wet AMD, CNV, Neovascular AMD, Neovascular Age-related Macular Degeneration, Choroidal Neovascularization
Interventions
ABBV-RGX-314, Ranibizumab (LUCENTIS®)
Genetic · Biological
Lead sponsor
AbbVie
Industry
Eligibility
50 Years to 89 Years
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
89
States / cities
Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 77 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 9, 2026, 4:01 AM EDT
Active, not recruiting No phase listed Observational

Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]

NCT04645212
View directory record Official record
Conditions
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration
Interventions
ADVM-022
Biological
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
9
States / cities
Bakersfield, California • Beverly Hills, California • Lakewood, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 9, 2026, 4:01 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

NCT07482176
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
79
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 9, 2026, 4:01 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Efficacy, Safety, and Immunogenicity With ABP 938 8 mg Versus EYLEA® HD (Aflibercept) in Participants With Neovascular Age-related Macular Degeneration

NCT07614776
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, nAMD
Interventions
ABP 938 8 mg, Aflibercept (US) 8 mg
Drug
Lead sponsor
Amgen
Industry
Eligibility
50 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
55
States / cities
Fullerton, California • Long Beach, California • Modesto, California + 50 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 9, 2026, 4:01 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

NCT05769153
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
AR-14034 SR implant lower dose, AR-14034 SR implant higher dose, AR-14034 SR implant, Aflibercept Injection, Sham procedure
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
42
States / cities
Dothan, Alabama • Gilbert, Arizona • Phoenix, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 9, 2026, 4:01 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of AKST4290 With Aflibercept in Patients With Newly Diagnosed nAMD

NCT04331730
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
AKST4290, Placebo, Aflibercept
Drug
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
50 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
3
States / cities
Beverly Hills, California • St. Petersburg, Florida • Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 9, 2026, 4:01 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy

NCT03999801
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Interventions
RGX-314
Genetic
Lead sponsor
AbbVie
Industry
Eligibility
50 Years and older
Enrollment
865 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
9
States / cities
Phoenix, Arizona • Santa Barbara, California • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 9, 2026, 4:01 AM EDT
Completed Phase 1 Interventional

Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration

NCT04989699
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
OTX-TKI/Sham, Aflibercept/Sham
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
6
States / cities
Bakersfield, California • Oxnard, California • Altamonte Springs, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2024 · Synced Oct 9, 2026, 4:01 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)

NCT06491914
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions
Aflibercept 8 mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
53
States / cities
Arcadia, California • Bakersfield, California • Beverly Hills, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 9, 2026, 4:01 AM EDT
Terminated Phase 3 Interventional Results available

Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections

NCT03710564
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Brolucizumab, Aflibercept
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
60
States / cities
Phoenix, Arizona • Beverly Hills, California • Huntington Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2023 · Synced Oct 9, 2026, 4:01 AM EDT
Completed Phase 1 Interventional

A Study of EXG102-031 in Patients With wAMD (Everest)

NCT05903794
View directory record Official record
Conditions
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
Interventions
EXG102-031
Biological
Lead sponsor
Exegenesis Bio
Industry
Eligibility
50 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Reno, Nevada • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 9, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

NCT05161806
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
SOK583A1 (40 mg/mL), Prefilled Syringe (PFS)
Drug · Device
Lead sponsor
Sandoz
Industry
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
3
States / cities
Marietta, Georgia • Oak Forest, Illinois • Liverpool, New York
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Oct 9, 2026, 4:01 AM EDT
Enrolling by invitation No phase listed Observational

Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

NCT07660640
View directory record Official record
Conditions
Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
Interventions
observational study, VOY-101
Other · Biological
Lead sponsor
Perceive Biotherapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 9, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye

NCT04423718
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Aflibercept High Dose VEGF Trap-Eye (BAY86-5321), Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)
Drug
Lead sponsor
Bayer
Industry
Eligibility
50 Years and older
Enrollment
1,011 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Phoenix, Arizona • Fullerton, California • Mountain View, California + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2025 · Synced Oct 9, 2026, 4:01 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients

NCT04635800
View directory record Official record
Conditions
Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
Interventions
MHU650
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
5
States / cities
Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 9, 2026, 4:01 AM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

NCT06856577
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Interventions
Ixo-vec, Aflibercept
Genetic · Drug
Lead sponsor
Adverum Biotechnologies, Inc.
Industry
Eligibility
50 Years and older
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
75
States / cities
Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 9, 2026, 4:01 AM EDT
Enrolling by invitation Phase 2 Interventional

Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD

NCT05210803
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
Standard of Care, Ranibizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
Not listed
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
16
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 9, 2026, 4:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial

NCT03066258
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration
Interventions
RGX-314
Genetic
Lead sponsor
REGENXBIO Inc.
Industry
Eligibility
50 Years to 89 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
8
States / cities
Santa Barbara, California • Baltimore, Maryland • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 9, 2026, 4:01 AM EDT
Completed Phase 1 Interventional

A Study Assessing AR-13503 Implant in Subjects With nAMD or DME

NCT03835884
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Interventions
AR-13503 Implant 10.6 Dose, AR-13503 Implant 21.2 Dose, AR-13503 42.4 Dose, AR-13503 63.6 Dose
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Gilbert, Arizona • Beverly Hills, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 9, 2026, 4:01 AM EDT
Terminated Phase 3 Interventional Results available

OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)

NCT04757610
View directory record Official record
Conditions
Neovascular Age-related Macular Degeneration
Interventions
2.0 mg OPT-302, 0.5 mg ranibizumab, Sham
Biological · Procedure
Lead sponsor
Opthea Limited
Industry
Eligibility
50 Years and older
Enrollment
986 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
76
States / cities
Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Oct 9, 2026, 4:01 AM EDT
Recruiting No phase listed Observational

A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD

NCT06346600
View directory record Official record
Conditions
Neovascular (Wet) Age-related Macular Degeneration
Interventions
SKG0106
Genetic
Lead sponsor
Skyline Therapeutics
Industry
Eligibility
50 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
3
States / cities
Boston, Massachusetts • Katy, Texas • Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 9, 2026, 4:01 AM EDT
Recruiting Phase 3 Interventional

Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants With Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OTX-TKI-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study

NCT07516132
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration (nAMD)
Interventions
OTX-TKI
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
50 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
8
States / cities
Bakersfield, California • Santa Barbara, California • Waterford, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 9, 2026, 4:01 AM EDT
Completed Phase 3 Interventional Results available

Comparing the Efficacy and Safety of Biosimilar Candidate Xlucane Versus Lucentis® in Patients With nAMD

NCT03805100
View directory record Official record
Conditions
Macular Degeneration
Interventions
Ranibizumab
Biological
Lead sponsor
Xbrane Biopharma AB
Industry
Eligibility
50 Years and older
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
26
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 9, 2026, 4:01 AM EDT
Completed No phase listed Observational

A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

NCT06769412
View directory record Official record
Conditions
Retinal Vasculitis
Interventions
aflibercept 2 mg
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 9, 2026, 4:01 AM EDT